SMO Overview

Alpha, Site Management Organization (SMO) offers operational, regulatory and other centralized research support services for sites on industry-sponsored and investigator-initiated trials. With access to a broad patient base, the SMO conducts and supports phase I through IV and outcomes-based trials throughout its network of sites.

Alpha works closely in partnership with the pharmaceutical study sponsors. Together, our precise data collection helps to develop treatments to improve the quality of life for participants around the world. We recognize the importance of timely start-up and thorough documentation processing from initial contact through completion. We offer a full spectrum of services designed to ensure the smooth operation and success of your trial. From study initiation to closeout, your project has a dedicated team committed to excellence and you.

The SMO offers support services for trials across tumor types including complex GI, lung, breast, central nervous system, genitourinary, melanoma and blood cancers.

Alpha is conveniently located in central Florida with easy access to the Daytona/Orlando International Airport, Central Florida Regional Hospital, AdventHealth, Halifax Health, hotel accommodations, and area attractions.

SMO Overview Highlights

  • 100+ patients enrolled per year across all sites
  • 100+ first-in-human clinical trials conducted
  • Clinical trial leader in the majority of approved cancer therapies over the last 10 years
  • 100+ patients enrolled in immunotherapy trials to date

Centralized Support Services:

  • Program Development & Start-up
  • Contracting & Financial Services
  • Regulatory & Safety
  • Clinical Operations Support
  • Quality Assurance
  • Technology Integration & Support

Our Differentiators:

  • Rapid Study Activation Timelines
  • Community Clinic-Based Model at Alpha Provides Access to Larger Numbers of Patients

For pharmaceutical study sponsors interested in contacting Alpha, please email the Regulatory Specialist, Kiran Penta, directly at Communications sent directly to the Regulatory Specialist will be handled with the highest priority.